Want to see CVSI full AI Analyst Report?
CVSI Stock Chart & Stats
$0.02
>-$0.01(-5.72%)
At close: 4:00 PM EDT
$0.02
>-$0.01(-5.72%)
Day’s Range― - ―
52-Week Range$0.02 - $0.10
Previous CloseN/A
Volume53.78K
Average Volume (3M)246.65K
Market Cap
$4.07M
Enterprise Value$7.26
Total Cash (Recent Filing)$309.00K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding203,977,520
10 Day Avg. Volume158,629
30 Day Avg. Volume246,649
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)7.71
Price to Sales (P/S)0.82
P/FCF Ratio-21.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Product Gross MarginsSustained high gross margins (~65% TTM) indicate strong unit economics for core CBD and wellness products. This provides durable margin levers to recover profitability if top-line stabilizes and supports margin resilience through cost and channel optimization over the next several quarters.
Direct‑to‑Consumer Channel StrengthA large DTC mix (44% of revenue) reduces dependence on wholesale placements and gives the company direct consumer insights, higher marginal economics, and more control over pricing and promotions—structural advantages that support durable revenue retention and margin improvement.
Operational Progress Toward Cash‑Flow BreakevenMeaningful cost cuts (~13% YoY SG&A), improved adjusted EBITDA and single‑quarter positive operating cash flow show management can translate initiatives into cash improvement. Combined with insourcing and M&A synergies, this supports a credible path to sustained positive OCF in H2 2026.
Bears Say
Declining Revenue And Unit SalesMaterial top-line contraction and falling unit volumes reflect persistent category weakness and indicate demand erosion. Continued revenue declines strain fixed-cost absorption and make achieving durable profitability and cash-flow stability harder without clear signs of secular demand recovery.
Negative Cash Flow And Low LiquidityOngoing negative operating and free cash flow, coupled with modest absolute debt, creates financing risk. Low cash balances limit the company's ability to fund marketing, inventory or new product launches sustainably, making execution of the turnaround and M&A integration riskier.
Regulatory And Category Structural RiskUnclear federal guidance and potential product restrictions are structural risks that can force reformulation, limit channels, or increase compliance costs. Combined with a contracting, fragmented CBD market, this reduces long‑term addressable demand and raises execution complexity for product expansion.
CV Sciences News
CVSI FAQ
What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
What is CV Sciences Inc’s market cap?
CV Sciences Inc’s market cap is $4.07M.
When is CV Sciences Inc’s upcoming earnings report date?
CV Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 14 days.
How were CV Sciences Inc’s earnings last quarter?
CV Sciences Inc released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is CV Sciences Inc overvalued?
According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued.
Does CV Sciences Inc pay dividends?
CV Sciences Inc does not currently pay dividends.
What is CV Sciences Inc’s EPS estimate?
CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CV Sciences Inc have?
CV Sciences Inc has 203,977,520 shares outstanding.
What happened to CV Sciences Inc’s price movement after its last earnings report?
CV Sciences Inc reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of CV Sciences Inc?
Currently, no hedge funds are holding shares in CVSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CV Sciences Inc
CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.
CVSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.View all CVSI earnings summariesTechnical Analysis
cbdMD
―
Cosmos Holdings
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―









